Suppression of connective tissue growth factor mediates the renoprotective effect of Sitagliptin rather than Pioglitazone in type 2 diabetes mellitus

Life Sciences

Volumn 153, Issue , 2016, Pages 180-187

  Ali, Samia M ^a   Khalifa, Hoda ^a   Mostafa, Dalia K ^a   El Sharkawy, Amal ^a  

^a ALEXANDRIA UNIVERSITY   (Egypt)

Author keywords

CTGF; Diabetic nephropathy; Enalapril; Metformin; Pioglitazone; Sitagliptin

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; CREATININE; ENALAPRIL; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LIPID; MALONALDEHYDE; METFORMIN; PIOGLITAZONE; SITAGLIPTIN; STREPTOZOCIN; UREA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COMPARATIVE EFFECTIVENESS; CONTROLLED STUDY; CREATININE BLOOD LEVEL; DIABETES CONTROL; DIET RESTRICTION; DRUG EFFICACY; DRUG MECHANISM; EXPERIMENTAL DIABETIC NEPHROPATHY; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HISTOPATHOLOGY; INSULIN BLOOD LEVEL; KIDNEY MASS; LIPID BLOOD LEVEL; LIPID DIET; MALE; MICROALBUMINURIA; MORNING DOSAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OXIDATIVE STRESS; PANCREAS ISLET BETA CELL; PANCREAS ISLET CELL FUNCTION; PROTEIN BLOOD LEVEL; RAT; RENAL PROTECTION; SINGLE DRUG DOSE; TROPISM; UREA BLOOD LEVEL; ANIMAL; METABOLISM; WISTAR RAT;

ANIMALS; CONNECTIVE TISSUE GROWTH FACTOR; HYPOGLYCEMIC AGENTS; MALE; RATS; RATS, WISTAR; SITAGLIPTIN PHOSPHATE; THIAZOLIDINEDIONES;

EID: 84966455255     PISSN: 00243205     EISSN: 18790631     Source Type: Journal    
DOI: 10.1016/j.lfs.2016.03.043     Document Type: Article

References (54)

1. C. Mega, E.T. de Lemos, H. Vala, R. Fernandes, J. Oliveira, F. Mascarenhas-Melo, F. Teixeira, and F. Reis Diabetic nephropathy amelioration by a low-dose Sitagliptin in animal model of type 2 diabetes (Zucker diabetic fatty rat) Exp. Diabetes Res. 2011 2011 162092 10.1155/2011/162092
2. A.B. Olokoba, O.A. Obateru, and L.B. Olokoba Type 2 diabetes mellitus: a review of current trends Oman Med. J. 27 4 2012 269 273 10.5001/omj.2012.68
3. N. Choudhary, and R.S. Ahlawat Interleukin-6 and C-reactive protein in pathogenesis of diabetic nephropathy: new evidence linking inflammation, glycemic control, and microalbuminuria Iran J. Kidney Dis. 2 2 2008 72 79
4. G.J. Ko, Y.S. Kang, S.Y. Han, M.H. Lee, H.K. Song, K.H. Han, H.K. Kim, J.Y. Han, and D.R. Cha Pioglitazone attenuates diabetic nephropathy through an anti-inflammatory mechanism in type 2 diabetic rats Nephrol. Dial. Transplant. 23 9 2008 2750 2760 10.1093/ndt/gfn157
5. T. Abel, and J. Fehér A new therapeutic possibility for type 2 diabetes: DPP-4 inhibitors (sitagliptin) Orv. Hetil. 151 25 2010 1012 1016 10.1556/OH.2010.28910
6. A.L. Sun, J.T. Deng, G.J. Guan, S.H. Chen, Y.T. Liu, J. Cheng, Z.W. Li, X.H. Zhuang, F.D. Sun, and H.P. Deng Dipeptidyl peptidase-IV is a potential molecular biomarker in diabetic kidney disease Diab. Vasc. Dis. Res. 9 4 2012 301 308
7. N.K. Hollenberg, D.A. Price, N.D. Fisher, M.C. Lansang, B. Perkins, M.S. Gordon, G.H. Williams, and L.M. Laffel Glomerular hemodynamics and the renin-angiotensin system in patients with type 1 diabetes mellitus Kidney Int. 63 2003 172 178
8. American Diabetes Association Standards of medical care in diabetes - 2014 Diabetes Care 37 Suppl. 1 2014 S14 S80 10.2337/dc14-S014
9. W.B. Reeves, and T.E. Andreoli Transforming growth factor beta contributes to progressive diabetic nephropathy Proc. Natl. Acad. Sci. U. S. A. 97 14 2000 7667 7669
10. O.V. Sakharova, M.W. Taal, and B.M. Brenner Pathogenesis of diabetic nephropathy: focus on transforming growth factor-beta and connective tissue growth factor Curr. Opin. Nephrol. Hypertens. 10 6 2001 727 738
11. T.Q. Nguyen, L. Tarnow, A. Jorsal, N. Oliver, P. Roestenberg, Y. Ito, H.H. Parving, P. Rossing, F.A. van Nieuwenhoven, and R. Goldschmeding Plasma connective tissue growth factor is an independent predictor of end-stage renal disease and mortality in type 1 diabetic nephropathy Diabetes Care 31 6 2008 1177 1182 10.2337/dc07-2469
12. K. Srinivasan, B. Viswanad, L. Asrat, C.L. Kaul, and P. Ramarao Combination of high-fat diet-fed and low-dose streptozotocin-treated rat: a model for type 2 diabetes and pharmacological screening Pharmacol. Res. 52 4 2005 313 320
13. M. El-Sayed, D. Ghareeb, H. Talat, and E. Sarhan High fat diet induced insulin resistance and elevated retinol binding protein 4 in female rats; treatment and protection with Berberis vulgaris extract and vitamin A PJPS 26 6 2013 1189 1195
14. A.E. El-Sahar, M.M. Safar, H.F. Zaki, A.S. Attia, and A.A. Ain-Shoka Neuroprotective effects of pioglitazone against transient cerebral ischemic reperfusion injury in diabetic rats: modulation of antioxidant, anti-inflammatory, and anti-apoptotic biomarkers Pharmacol. Rep. 67 5 2015 901 906 10.1016/j.pharep.2015.03.018
15. T.K. Motawi, S.A. El-Maraghy, and M.A. Senousy Angiotensin-converting enzyme inhibition and angiotensin AT1 receptor blockade downregulate angiotensin-converting enzyme expression and attenuate renal injury in streptozotocin-induced diabetic rats J. Biochem. Mol. Toxicol. 27 7 2013 378 387 10.1002/jbt.21500
16. B. Wessels, J. Ciapaite, N.M. van den Broek, K. Nicolay, and J.J. Prompers Metformin impairs mitochondrial function in skeletal muscle of both lean and diabetic rats in a dose-dependent manner PLoS ONE 9 6 2014 e100525 10.1371/journal.pone.0100525
17. D. Barham, and P. Trinder An improved color reagent for the de-termination of blood glucose by the oxidase system Analyst 97 1972 142 145
18. J. Karl, G. Burns, W.D. Engel, A. Finke, and M. Kratzer Development and standardization of the new immunoturbidimetric HgA1c assay Klin. Lab. 39 1993 991 996
19. L. Thomas Clinical Laboratory Diagnostics first ed. 1998 TH-Books Verlagsgesellschaft Frankfurt 208 214
20. L.D. Elving, J.A.M. Bakkeren, M.J.H. Jansen, C.M. de Kat Angelino, E. de Nobel, and P.J.J. Van Munster Microalbuminuria Clin. Chem. 35 1989 308 311
21. www.dtu.ox.ac.uk/homa
22. H. Ohkawa, N. Ohnishi, and K. Yagi Assay for lipid peroxides for animal tissues by thiobarbituric acid reaction Anal. Biochem. 95 1979 351 358
23. V. Harjutsalo, and P.H. Groop Epidemiology and risk factors for diabetic kidney disease Adv. Chronic Kidney Dis. 21 3 2014 260 266 10.1053/j.ackd.2014.03.009
24. J.J. Holst, T. Vilsbøll, and C.F. Deacon The incretin system and its role in type 2 diabetes mellitus Mol. Cell. Endocrinol. 297 1-2 2009 127 136 10.1016/j.mce.2008.08.012
25. M. Radenković Pioglitazone and endothelial dysfunction: pleiotropic effects and possible therapeutic implications Sci. Pharm. 82 4 2014 709 721 10.3797/scipharm.1407-16
26. L. Sun, N. Halaihel, W. Zhang, T. Rogers, and M. Levi Role of sterol regulatory element-binding protein 1 in regulation of renal lipid metabolism and glomerulosclerosis in diabetes mellitus J. Biol. Chem. 277 21 2002 18919 18927
27. M. Sugano, H. Yamato, T. Hayashi, H. Ochiai, J. Kakuchi, S. Goto, F. Nishijima, N. Iino, J.J. Kazama, T. Takeuchi, O. Mokuda, T. Ishikawa, and R. Okazaki High-fat diet in low-dose-streptozotocin-treated heminephrectomized rats induces all features of human type 2 diabetic nephropathy: a new rat model of diabetic nephropathy Nutr. Metab. Cardiovasc. Dis. 16 7 2006 477 484
28. D.T. Peterson, W.C. Greene, and G.M. Reaven Effect of experimental diabetes mellitus on kidney ribosomal protein synthesis Diabetes 20 10 1971 649 654
29. H. Mori, Y. Okada, T. Arao, and Y. Tanaka Sitagliptin improves albuminuria in patients with type 2 diabetes mellitus J. Diabetes Investig. 5 3 2014 313 319 10.1111/jdi.12142
30. M.C. Hsieh, Y.T. Hsieh, T.J. Cho, J.F. Chen, S.D. Lin, H.C. Chen, and S.T. Tu Remission of diabetic nephropathy in type 2 diabetic Asian population: role of tight glucose and blood pressure control Eur. J. Clin. Investig. 41 8 2011 870 878 10.1111/j.1365-2362.2011.02479.x
31. J. Mu, A. Petrov, G.J. Eiermann, J. Woods, Y.P. Zhou, Z. Li, E. Zycband, Y. Feng, L. Zhu, R.S. Roy, A.D. Howard, C. Li, N.A. Thornberry, and B.B. Zhang Inhibition of DPP-4 with sitagliptin improves glycemic control and restores islet cell mass and function in a rodent model of type 2 diabetes Eur. J. Pharmacol. 623 1-3 2009 148 154 10.1016/j.ejphar.2009.09.027
32. J. Li, M. Guan, C. Li, F. Lyv, Y. Zeng, Z. Zheng, C. Wang, and Y. Xue The dipeptidyl peptidase-4 inhibitor sitagliptin protects against dyslipidemia-related kidney injury in Apolipoprotein E knockout mice Int. J. Mol. Sci. 15 7 2014 11416 11434 10.3390/ijms150711416
33. A.J. Tremblay, B. Lamarche, C.F. Deacon, S.J. Weisnagel, and P. Couture Effect of sitagliptin therapy on postprandial lipoprotein levels in patients with type 2 diabetes Diabetes Obes. Metab. 13 4 2011 366 373 10.1111/j.1463-1326.2011.01362.x
34. M. Monami, C. Lamanna, C.M. Desideri, and E. Mannucci DPP-4 inhibitors and lipids: systematic review and meta-analysis Adv. Ther. 29 1 2012 14 25 10.1007/s12325-011-0088-z
35. R.F. Rosario, and S. Prabhakar Lipids and diabetic nephropathy Curr. Diab. Rep. 6 6 2006 455 462
36. M. Lassila, K.K. Seah, T.J. Allen, V. Thallas, M.C. Thomas, R. Candido, W.C. Burns, J.M. Forbes, A.C. Calkin, M.E. Cooper, and K.A. Jandeleit-Dahm Accelerated nephropathy in diabetic apolipoprotein e-knockout mouse: role of advanced glycation end products J. Am. Soc. Nephrol. 15 8 2004 2125 2138
37. P.N. Chander, O. Gealekman, S.V. Brodsky, S. Elitok, A. Tojo, M. Crabtree, S.S. Gross, and M.S. Goligorsky Nephropathy in Zucker diabetic fat rat is associated with oxidative and nitrosative stress: prevention by chronic therapy with a peroxynitrite scavenger ebselen J. Am. Soc. Nephrol. 15 9 2004 2391 2403
38. Y. Suzaki, Y. Ozawa, and H. Kobori Internal oxidative stress and augmented angiotensinogen are precedent to renal injury in Zucker diabetic fattyrats Int. J. Biol. Sci. 3 1 2006 40 46
39. L. Ferreira, E. Teixeira-de-Lemos, F. Pinto, B. Parada, C. Mega, H. Vala, R. Pinto, P. Garrido, J. Sereno, R. Fernandes, P. Santos, I. Velada, A. Melo, S. Nunes, F. Teixeira, and F. Reis Effects of sitagliptin treatment on dysmetabolism, inflammation, and oxidative stress in an animal model of type 2 diabetes (ZDF rat) Mediat. Inflamm. 2010 2010 592760 10.1155/2010/592760
40. J. Asakura, H. Hasegawa, K. Takayanagi, T. Shimazu, R. Suge, T. Shimizu, T. Iwashita, Y. Tayama, A. Matsuda, K. Kanozawa, N. Araki, and T. Mitarai Renoprotective effect of pioglitazone by the prevention of glomerular hyperfiltration through the possible restoration of altered macula densa signaling in rats with type 2 diabetic nephropathy Nephron Exp. Nephrol. 122 3-4 2012 83 94 10.1159/000348661
41. P.A. Sarafidis, and G.L. Bakris Protection of the kidney by thiazolidinediones: an assessment from bench to bedside Kidney Int. 70 7 2006 1223 1233
42. T. Tang, J. Glanville, C.J. Hayden, D. White, J.H. Barth, and A.H. Balen Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study Hum. Reprod. 21 1 2006 80 89
43. A. El Midaoui, L. Wu, R. Wang, and J. de Champlain Modulation of cardiac and aortic peroxisome proliferator-activated receptor-gamma expression by oxidative stress in chronically glucose-fed rats Am. J. Hypertens. 19 4 2006 407 412
44. B. Reel, M. Guzeloglu, A. Bagriyanik, S. Atmaca, K. Aykut, G. Albayrak, and E. Hazan The effects of PPAR-γ agonist pioglitazone on renal ischemia/reperfusion injury in rats J. Surg. Res. 182 1 2013 176 184 10.1016/j.jss.2012.08.020
45. M. Kuru Karabas, M. Ayhan, E. Guney, M. Serter, and I. Meteoglu The effect of pioglitazone on antioxidant levels and renal histopathology in streptozotocin-induced diabetic rats ISRN Endocrinol. 2013 2013 858690 10.1155/2013/858690
46. G. Setti, A. Hayward, C. Dessapt, F. Barone, R. Buckingham, K. White, R. Bilous, K. Hiroshi, G. Gruden, G. Viberti, and L. Gnudi Peroxisome proliferator activated receptor-gamma agonist rosiglitazone prevents albuminuria but not glomerulosclerosis in experimental diabetes Am. J. Nephrol. 32 2010 393 402 10.1159/000320129
47. K.G. Gerritsen, J.W. Leeuwis, M.P. Koeners, S.J. Bakker, W. van Oeveren, J. Aten, L. Tarnow, P. Rossing, J.F. Wetzels, J.A. Joles, R.J. Kok, R. Goldschmeding, and T.Q. Nguyen Elevated urinary connective tissue growth factor in diabetic nephropathy is caused by local production and tubular dysfunction J. Diabetes Res. 2015 2015 539787 10.1155/2015/539787
48. S.G. Adler, S.W. Kang, S. Feld, D.R. Cha, L. Barba, L. Striker, G. Striker, B.L. Riser, J. LaPage, and C.C. Nast Glomerular mRNAs in human type 1 diabetes: biochemical evidence for microalbuminuria as a manifestation of diabetic nephropathy Kidney Int. 60 2001 2330 2336
49. P. Roestenberg, F.A. van Nieuwenhoven, L. Wieten, P. Boer, T. Diekman, A.M. Tiller, W.M. Wiersinga, N. Oliver, W. Usinger, S. Weitz, R.O. Schlingemann, and R. Goldschmeding Connective tissue growth factor is increased in plasma of type 1 diabetic patients with nephropathy Diabetes Care 27 5 2004 1164 1170
50. R.E. Gilbert, A. Akdeniz, S. Weitz, W.R. Usinger, C. Molineaux, S.E. Jones, R.G. Langham, and G. Jerums Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy Diabetes Care 26 2003 2632 2636
51. K. Koga, H. Yokoi, K. Mori, M. Kasahara, T. Kuwabara, H. Imamaki, A. Ishii, K.P. Mori, Y. Kato, S. Ohno, N. Toda, M.A. Saleem, A. Sugawara, K. Nakao, M. Yanagita, and M. Mukoyama MicroRNA-26-26a inhibits TGF-β-induced extracellular matrix protein expression in podocytes by targeting CTGF and is downregulated in diabetic nephropathy Diabetologia 58 9 2015 2169 2180 10.1007/s00125-015-3642-4
52. S. Lam, N.A.M. Verhagen, R.N. van der Geest, F.A. van Nieuwenhoven, I.E. Blom, J. Aten, R. Goldschmeding, M.R. Daha, and C. van Kooten Connective tissue growth factor and IGF-I are produced by human renal fibroblasts, and cooperate in the induction of collagen production by high glucose Diabetes 52 2003 2975 2983
53. J.G. Abreu, N.I. Ketpura, B. Reversade, and E.M. De Robertis Connective-tissue growth factor (CTGF) modulates cell signalling by BMP and TGF-beta Nat. Cell Biol. l4 2002 599 604
54. B. Picatoste, E. Ramírez, A. Caro-Vadillo, C. Iborra, S. Ares-Carrasco, J. Egido, J. Tuñón, and O. Lorenzo Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-ii diabetes. Potential roles of GLP-1 isoforms PLoS ONE 8 10 2013 e78330 10.1371/journal.pone.0078330